Citations as recorded by:

1. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer

Cancer Chemother Pharmacol, 2017, 80(3) p. 653

DOI: 10.1007/s00280-017-3379-5

Citations as recorded by: Cross Ref

2. Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers

Therapeutic Drug Monitoring, 2017, 39(4) p. 406

DOI: 10.1097/FTD.0000000000000415

Citations as recorded by: Cross Ref

3. Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population

Pharmacogenomics, 2017, 18(4) p. 369

DOI: 10.2217/pgs-2016-0179

Citations as recorded by: Cross Ref

4. Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs

Therapeutic Drug Monitoring, 2016, 38 p. S57

DOI: 10.1097/FTD.0000000000000255

Citations as recorded by: Cross Ref

5. CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients

SpringerPlus, 2015, 4(1)

DOI: 10.1186/s40064-015-1425-5

Citations as recorded by: Cross Ref

6. Sirolimus and everolimus in kidney transplantation

Drug Discovery Today, 2015, 20(10) p. 1243

DOI: 10.1016/j.drudis.2015.05.006

Citations as recorded by: Cross Ref

7. The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient

Curr Cardiol Rep, 2015, 17(11)

DOI: 10.1007/s11886-015-0647-z

Citations as recorded by: Cross Ref

8. Functional Gene Variants of CYP3A4

Clin Pharmacol Ther, 2014, 96(3) p. 340

DOI: 10.1038/clpt.2014.129

Citations as recorded by: Cross Ref

9. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks

Br J Clin Pharmacol, 2014, 77(4) p. 715

DOI: 10.1111/bcp.12253

Citations as recorded by: Cross Ref

10. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients

Clin Transplant, 2014, 28(5) p. 590

DOI: 10.1111/ctr.12350

Citations as recorded by: Cross Ref

11. PharmGKB summary

Pharmacogenetics and Genomics, 2013, 23(10) p. 563

DOI: 10.1097/FPC.0b013e328364db84

Citations as recorded by: PMC C.0b013e328364db84" class="size14" target="_blank"> Cross Ref

12. Hepatotoxicity and Drug Interactions in Liver Transplant Candidates and Recipients

Clinics in Liver Disease, 2013, 17(4) p. 737

DOI: 10.1016/j.cld.2013.07.013

Citations as recorded by: Cross Ref

13. CYP450 Pharmacogenetic treatment strategies for antipsychotics: A review of the evidence

Schizophrenia Research, 2013, 149(1-3) p. 1

DOI: 10.1016/j.schres.2013.06.035

Citations as recorded by: Cross Ref